mavorixafor
Sponsor X4 Pharmaceuticals, INC · listed as XFOR
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
mavorixafor is a clinical-stage drug asset sponsored by X4 Pharmaceuticals, INC, listed as XFOR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 2027 (month precision, medium confidence), tied to trial NCT06056297. The asset is in Phase 3 and currently recruiting, studied in Neutropenia.
Next catalyst
Event typeREADOUT
Expected date2027-09-30
As disclosedSep 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06056297
PhasePHASE3
StatusRECRUITING
Lead sponsorX4 Pharmaceuticals
Listed asXFOR
Condition(s)Neutropenia
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More XFOR catalysts